Rosati Shannon, Maarouf Rami, Brown Karen, Poppe Michael, Parrish Dan, Haynes Jeffrey, Lanning David
Virginia Commonwealth University Health System, Division of Pediatric Surgery, Department of General Surgery, Children's Hospital of Richmond, Richmond, Virginia.
Virginia Commonwealth University School of Medicine, Richmond, Virginia.
J Surg Res. 2015 Oct;198(2):355-9. doi: 10.1016/j.jss.2015.03.071. Epub 2015 Mar 30.
The most common cause of precocious puberty is idiopathic central precocious puberty (CPP), which is usually treated with monthly injections. An alternative treatment of precious puberty is a subcutaneous implant that contains histrelin acetate, which is continuously released for more than 1 y and then removed or replaced with a new implant.
The aim of this study was to conduct a retrospective review of one surgeon's experience with the histrelin implant and to examine patient satisfaction. After obtaining institutional review board approval, the charts of all children who had undergone at least one implant were reviewed.
Fifty-eight children, average age 8.4 y old (range 7-14), underwent at least one histrelin implant insertion for treatment of CPP. Parents of 44 patients were able to be reached by telephone for this study and rated the histrelin implant treatment highly. All implants were placed, replaced, or removed without significant difficulty, and there were no complications.
This study suggests that the use of a histrelin subcutaneous implant for control of CPP is a safe and effective method for the treatment of this condition.
性早熟最常见的原因是特发性中枢性性早熟(CPP),通常采用每月注射进行治疗。性早熟的一种替代治疗方法是皮下植入含醋酸组氨瑞林的植入物,该植入物可持续释放超过1年,之后取出或更换新的植入物。
本研究的目的是回顾一位外科医生使用组氨瑞林植入物的经验,并调查患者满意度。在获得机构审查委员会批准后,对所有接受过至少一次植入物的儿童病历进行了回顾。
58名儿童(平均年龄8.4岁,范围7 - 14岁)接受了至少一次组氨瑞林植入物植入以治疗CPP。本研究通过电话联系到了44名患者的家长,他们对组氨瑞林植入物治疗评价很高。所有植入物的放置、更换或取出均无明显困难,且无并发症发生。
本研究表明,使用组氨瑞林皮下植入物控制CPP是治疗该疾病的一种安全有效的方法。